C.RIS Pharma, partner of the project PKD-STOP, is developing a new transgenic model of polycystic kidney disease. This project is granted by Europe (FEDER) and Région Bretagne.
Partners: C.RIS PHARMA, MANROS Therapeutics and IGDR
PKD-STOP: Treatment of polycystic kidney disease with kinase inhibitors.
C.RIS Pharma, partner of the project VIPP, is developping an in vitro cell model to evaluate anti-stress active drugs. This project is granted by Europe, Région Bretagne and St Malo Agglomération.
Partners: C.RIS PHARMA, ABYSS INGREDIENTS, PROTIM, CAPSULARIS, IDMER
VIPP: VERY IMPORTANT PREMIUM PEPTIDES
